Data / Drug companies / Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries, Inc.: 159 products in the FDA NDC directory, labeler code 47335
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sun Pharmaceutical Industries, Inc. (labeler code 47335) lists 159 products in the FDA National Drug Code Directory, covering 64 finished drugs by generic name. By type: 158 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 6, 2026.
The request: Watch Sun Pharmaceutical Industries, Inc. (FDA labeler code 47335): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 47335
- Products in commercial distribution
- 159
- Packages
- 495
- Finished drugs by generic name
- 64
- Prescription products
- 158
- Over the counter products
- 1
- Controlled substance products
- Schedule IV 11, Schedule V 12
- Flagged as original packager
- 156 of 156 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- May 31, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 141 | 88.7% |
| New drug applications (NDA) | 16 | 10.1% |
| Authorized generics (NDA) | 1 | 0.6% |
| Biologics (BLA) | 1 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 158 | 99.4% |
| Over the counter drugs | 1 | 0.6% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 47 | 29.6% |
| Capsule | 18 | 11.3% |
| Capsule, extended release | 13 | 8.2% |
| Tablet, extended release | 12 | 7.5% |
| Tablet, film coated, extended release | 10 | 6.3% |
| Tablet | 9 | 5.7% |
| Solution | 8 | 5% |
| Injection, solution | 8 | 5% |
| Capsule, delayed release | 7 | 4.4% |
| Solution/ drops | 7 | 4.4% |
| Injection | 5 | 3.1% |
| Suspension | 3 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Macitentan | 47335-070 | Tablet, film coated | Generic drugs (ANDA) | June 6, 2026 |
| Sumatriptan Succinate | 47335-276 | Injection | Generic drugs (ANDA) | August 20, 2025 |
| Glatiramer Acetate | 47335-991 | Injection, solution | Generic drugs (ANDA) | August 15, 2025 |
| Glatiramer Acetate | 47335-990 | Injection, solution | Generic drugs (ANDA) | August 15, 2025 |
| Leqselvi | 47335-108 | Tablet, film coated | New drug applications (NDA) | June 25, 2025 |
| Drizalma sprinkle | 47335-619 | Capsule, delayed release | New drug applications (NDA) | June 10, 2024 |
| Drizalma sprinkle | 47335-618 | Capsule, delayed release | New drug applications (NDA) | June 10, 2024 |
| Drizalma sprinkle | 47335-617 | Capsule, delayed release | New drug applications (NDA) | June 10, 2024 |
| Drizalma sprinkle | 47335-616 | Capsule, delayed release | New drug applications (NDA) | June 10, 2024 |
| Lurasidone Hydrochloride | 47335-685 | Tablet | Generic drugs (ANDA) | February 20, 2023 |
| Lurasidone Hydrochloride | 47335-684 | Tablet | Generic drugs (ANDA) | February 20, 2023 |
| Lurasidone Hydrochloride | 47335-639 | Tablet | Generic drugs (ANDA) | February 20, 2023 |
| Lurasidone Hydrochloride | 47335-579 | Tablet | Generic drugs (ANDA) | February 20, 2023 |
| Lurasidone Hydrochloride | 47335-578 | Tablet | Generic drugs (ANDA) | February 20, 2023 |
| Ketorolac tromethamine | 47335-935 | Injection | Generic drugs (ANDA) | December 25, 2022 |
| Ketorolac tromethamine | 47335-934 | Injection | Generic drugs (ANDA) | December 25, 2022 |
| Ketorolac tromethamine | 47335-933 | Injection | Generic drugs (ANDA) | December 25, 2022 |
| Finasteride | 47335-714 | Tablet, film coated | Generic drugs (ANDA) | November 23, 2022 |
| Lacosamide | 47335-980 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 47335-943 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 47335-922 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 47335-918 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Aspruzyo sprinkle | 47335-625 | Granule | New drug applications (NDA) | February 28, 2022 |
| Ipratropium Bromide and Albuterol Sulfate | 47335-756 | Solution | Generic drugs (ANDA) | November 15, 2021 |
| Winlevi | 47335-994 | Cream | New drug applications (NDA) | October 4, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.